{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T02:45:08Z","timestamp":1784774708908,"version":"3.55.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2008,11]]},"DOI":"10.1007\/s10067-008-0964-3","type":"journal-article","created":{"date-parts":[[2008,7,31]],"date-time":"2008-07-31T10:03:21Z","timestamp":1217498601000},"page":"1343-1353","source":"Crossref","is-referenced-by-count":29,"title":["Abatacept: a T-cell co-stimulation modulator for the treatment of rheumatoid arthritis"],"prefix":"10.1007","volume":"27","author":[{"given":"Andrew J K","family":"\u00d6st\u00f6r","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2008,8,1]]},"reference":[{"key":"964_CR1","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1093\/rheumatology\/kel054","volume":"45","author":"E Solau-Gervais","year":"2006","unstructured":"Solau-Gervais E, Laxenaire N, Cortet B et al (2006) Lack of efficacy of a third tumour necrosis factor alpha antagonist after failure of a soluble receptor and a monoclonal antibody. Rheumatology (Oxford) 45:1121\u20131124","journal-title":"Rheumatology (Oxford)"},{"key":"964_CR2","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1136\/ard.2006.058776","volume":"66","author":"F Iannone","year":"2007","unstructured":"Iannone F, Trotta F, Montecucco C et al (2007) Etanercept maintains the clinical benefit achieved by infliximab in patients with rheumatoid arthritis who discontinued infliximab because of side effects. Ann Rheum Dis 66:249\u2013252","journal-title":"Ann Rheum Dis"},{"key":"964_CR3","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1084\/jem.174.3.561","volume":"174","author":"PS Linsley","year":"1991","unstructured":"Linsley PS, Brady W, Urnes M et al (1991) CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med 174:561\u2013569","journal-title":"J Exp Med"},{"key":"964_CR4","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1053\/berh.2002.0257","volume":"16","author":"DP Symmons","year":"2002","unstructured":"Symmons DP (2002) Epidemiology of rheumatoid arthritis: determinants of onset, persistence and outcome. Best Pract Res Clin Rheumatol 16:707\u2013722","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"964_CR5","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1093\/rheumatology\/kel066","volume":"45","author":"R Westhovens","year":"2006","unstructured":"Westhovens R, Cole JC, Li T et al (2006) Improved health-related quality of life for rheumatoid arthritis patients treated with abatacept who have inadequate response to anti-TNF therapy in a double-blind, placebo-controlled, multicentre randomized clinical trial. Rheumatology (Oxford) 45:1238\u20131246","journal-title":"Rheumatology (Oxford)"},{"key":"964_CR6","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/art.1780310302","volume":"31","author":"FC Arnett","year":"1988","unstructured":"Arnett FC, Edworthy SM, Bloch DA et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315\u2013324","journal-title":"Arthritis Rheum"},{"key":"964_CR7","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1093\/rheumatology\/33.3.249","volume":"33","author":"GS Clarke","year":"1994","unstructured":"Clarke GS, Buckland-Wright JC, Grahame R (1994) Symmetry of radiological features in the wrist and hands of patients with early to moderate rheumatoid arthritis: a quantitative microfocal radiographic study. Br J Rheumatol 33:249\u2013254","journal-title":"Br J Rheumatol"},{"key":"964_CR8","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1002\/msc.104","volume":"5","author":"H Piper","year":"2007","unstructured":"Piper H, Douglas KM, Treharne GJ et al (2007) Prevalence and predictors of ocular manifestations of RA: is there a need for routine screening? Musculoskeletal Care 5:102\u2013117","journal-title":"Musculoskeletal Care"},{"key":"964_CR9","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1097\/01.mcp.0000239552.55326.ee","volume":"12","author":"DS Kim","year":"2006","unstructured":"Kim DS (2006) Interstitial lung disease in rheumatoid arthritis: recent advances. Curr Opin Pulm Med 12:346\u2013353","journal-title":"Curr Opin Pulm Med"},{"key":"964_CR10","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.berh.2006.05.001","volume":"20","author":"J Levin","year":"2006","unstructured":"Levin J, Werth VP (2006) Skin disorders with arthritis. Best Pract Res Clin Rheumatol 20:809\u2013826","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"964_CR11","doi-asserted-by":"crossref","first-page":"IV4","DOI":"10.1093\/rheumatology\/kel313","volume":"45","author":"AE Voskuyl","year":"2006","unstructured":"Voskuyl AE (2006) The heart and cardiovascular manifestations in rheumatoid arthritis. Rheumatology (Oxford) 45:IV4\u2013IV7","journal-title":"Rheumatology (Oxford)"},{"key":"964_CR12","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S1568-9972(03)00006-5","volume":"2","author":"G Cooper","year":"2003","unstructured":"Cooper G, Stroehla B (2003) The epidemiology of autoimmune diseases. Autoimmun Rev 2:119\u2013125","journal-title":"Autoimmun Rev"},{"key":"964_CR13","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1016\/S0140-6736(07)60784-3","volume":"370","author":"JS Smolen","year":"2007","unstructured":"Smolen JS, Aletaha D, Koeller M et al (2007) New therapies for treatment of rheumatoid arthritis. Lancet 370:1861\u20131874","journal-title":"Lancet"},{"key":"964_CR14","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/art.22331","volume":"56","author":"KL Hyrich","year":"2007","unstructured":"Hyrich KL, Lunt M, Watson KD et al (2007) Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study. Arthritis Rheum 56:13\u201320","journal-title":"Arthritis Rheum"},{"key":"964_CR15","first-page":"85","volume":"25","author":"E Poi Di","year":"2007","unstructured":"Di Poi E, Perin A, Morassi MP et al (2007) Switching to etanercept in patients with rheumatoid arthritis with no response to infliximab. Clin Exp Rheumatol 25:85\u201387","journal-title":"Clin Exp Rheumatol"},{"key":"964_CR16","first-page":"795","volume":"23","author":"G Cohen","year":"2005","unstructured":"Cohen G, Courvoisier N, Cohen JD et al (2005) The efficiency of switching from infliximab to etanercept and vice-versa in patients with rheumatoid arthritis. Clin Exp Rheumatol 23:795\u2013800","journal-title":"Clin Exp Rheumatol"},{"key":"964_CR17","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1080\/03009740510026887","volume":"34","author":"MC Wick","year":"2005","unstructured":"Wick MC, Ernestam S, Lindblad S et al (2005) Adalimumab (Humira) restores clinical response in patients with secondary loss of efficacy from infliximab (Remicade) or etanercept (Enbrel): results from the STURE registry at Karolinska University Hospital. Scand J Rheumatol 34:353\u2013358","journal-title":"Scand J Rheumatol"},{"key":"964_CR18","doi-asserted-by":"crossref","first-page":"R29","DOI":"10.1186\/ar1881","volume":"8","author":"JJ Gomez-Reino","year":"2006","unstructured":"Gomez-Reino JJ, Carmona L (2006) Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period. Arthritis Res Ther 8:R29","journal-title":"Arthritis Res Ther"},{"key":"964_CR19","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1038\/nrd2085","volume":"5","author":"JL Browning","year":"2006","unstructured":"Browning JL (2006) B cells move to centre stage: novel opportunities for autoimmune disease treatment. Nat Rev Drug Discov 5:564\u2013576","journal-title":"Nat Rev Drug Discov"},{"key":"964_CR20","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1182\/blood.V83.2.435.435","volume":"83","author":"ME Reff","year":"1994","unstructured":"Reff ME, Carner K, Chambers KS et al (1994) Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 83:435\u2013445","journal-title":"Blood"},{"key":"964_CR21","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1053\/sonc.2002.30156","volume":"29","author":"DG Maloney","year":"2002","unstructured":"Maloney DG, Smith B, Rose A (2002) Rituximab: mechanism of action and resistance. Semin Oncol 29:2\u20139","journal-title":"Semin Oncol"},{"key":"964_CR22","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1056\/NEJM200103223441207","volume":"344","author":"EH Choy","year":"2001","unstructured":"Choy EH, Panayi GS (2001) Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 344:907\u2013916","journal-title":"N Engl J Med"},{"key":"964_CR23","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1681\/ASN.V132559","volume":"13","author":"A Yamada","year":"2002","unstructured":"Yamada A, Salama AD, Sayegh MH (2002) The role of novel T cell costimulatory pathways in autoimmunity and transplantation. J Am Soc Nephrol 13:559\u2013575","journal-title":"J Am Soc Nephrol"},{"key":"964_CR24","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1002\/eji.200526000","volume":"35","author":"H Burkhardt","year":"2005","unstructured":"Burkhardt H, Sehnert B, Bockermann R et al (2005) Humoral immune response to citrullinated collagen type II determinants in early rheumatoid arthritis. Eur J Immunol 35:1643\u20131652","journal-title":"Eur J Immunol"},{"key":"964_CR25","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/j.0105-2896.2005.00327.x","volume":"208","author":"S Tanaka","year":"2005","unstructured":"Tanaka S, Nakamura K, Takahasi N et al (2005) Role of RANKL in physiological and pathological bone resorption and therapeutics targeting the RANKL\u2013RANK signaling system. Immunol Rev 208:30\u201349","journal-title":"Immunol Rev"},{"key":"964_CR26","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1046\/j.1440-1711.2002.01118.x","volume":"80","author":"PD Cravens","year":"2002","unstructured":"Cravens PD, Lipsky PE (2002) Dendritic cells, chemokine receptors and autoimmune inflammatory diseases. Immunol Cell Biol 80:497\u2013505","journal-title":"Immunol Cell Biol"},{"key":"964_CR27","first-page":"2204","volume":"34","author":"PM Davis","year":"2007","unstructured":"Davis PM, Abraham R, Xu L et al (2007) Abatacept binds to the Fc receptor CD64 but does not mediate complement-dependent cytotoxicity or antibody-dependent cellular cytotoxicity. J Rheumatol 34:2204\u20132210","journal-title":"J Rheumatol"},{"key":"964_CR28","first-page":"2162","volume":"33","author":"MH Weisman","year":"2006","unstructured":"Weisman MH, Durez P, Hallegua D et al (2006) Reduction of inflammatory biomarker response by abatacept in treatment of rheumatoid arthritis. J Rheumatol 33:2162\u20132166","journal-title":"J Rheumatol"},{"key":"964_CR29","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1056\/NEJMoa050524","volume":"353","author":"MC Genovese","year":"2005","unstructured":"Genovese MC, Becker JC, Schiff M et al (2005) Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med 353:1114\u20131123","journal-title":"N Engl J Med"},{"key":"964_CR30","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1136\/ard.2007.074773","volume":"67","author":"MC Genovese","year":"2007","unstructured":"Genovese MC, Schiff M, Luggen M et al (2007) Efficacy and safety of the selective co-stimulation modulator abatacept following 2\u00a0years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-TNF therapy. Ann Rheum Dis 67:547\u2013554","journal-title":"Ann Rheum Dis"},{"key":"964_CR31","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/art.1780380602","volume":"38","author":"DT Felson","year":"1995","unstructured":"Felson DT, Anderson JJ, Boers M et al (1995) American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 38:727\u2013735","journal-title":"Arthritis Rheum"},{"key":"964_CR32","first-page":"280","volume":"34","author":"G Wells","year":"2007","unstructured":"Wells G, Li T, Maxwell L et al (2007) Determining the minimal clinically important differences in activity, fatigue, and sleep quality in patients with rheumatoid arthritis. J Rheumatol 34:280\u2013289","journal-title":"J Rheumatol"},{"key":"964_CR33","first-page":"557","volume":"20","author":"GA Wells","year":"1993","unstructured":"Wells GA, Tugwell P, Kraag GR et al (1993) Minimum important difference between patients with rheumatoid arthritis: the patient\u2019s perspective. J Rheumatol 20:557\u2013560","journal-title":"J Rheumatol"},{"key":"964_CR34","first-page":"1174","volume":"34","author":"JR Kirwan","year":"2007","unstructured":"Kirwan JR, Minnock P, Adebajo A et al (2007) Patient perspective: fatigue as a recommended patient centered outcome measure in rheumatoid arthritis. J Rheumatol 34:1174\u20131177","journal-title":"J Rheumatol"},{"key":"964_CR35","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","volume":"30","author":"JE Ware Jr.","year":"1992","unstructured":"Ware JE Jr., Sherbourne CD (1992) The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 30:473\u2013483","journal-title":"Med Care"},{"key":"964_CR36","doi-asserted-by":"crossref","first-page":"141","DOI":"10.2165\/00019053-199915020-00003","volume":"15","author":"G Samsa","year":"1999","unstructured":"Samsa G, Edelman D, Rothman ML et al (1999) Determining clinically important differences in health status measures: a general approach with illustration to the Health Utilities Index Mark II. Pharmacoeconomics 15:141\u2013155","journal-title":"Pharmacoeconomics"},{"key":"964_CR37","doi-asserted-by":"crossref","first-page":"865","DOI":"10.7326\/0003-4819-144-12-200606200-00003","volume":"144","author":"JM Kremer","year":"2006","unstructured":"Kremer JM, Genant HK, Moreland LW et al (2006) Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann Intern Med 144:865\u2013876","journal-title":"Ann Intern Med"},{"key":"964_CR38","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1002\/art.23397","volume":"58","author":"JM Kremer","year":"2008","unstructured":"Kremer JM, Genant HK, Moreland LW et al (2008) Results of a two-year followup study of patients with rheumatoid arthritis who received a combination of abatacept and methotrexate. Arthritis Rheum 58:953\u2013963","journal-title":"Arthritis Rheum"},{"key":"964_CR39","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1136\/ard.2007.085084","volume":"67","author":"HK Genant","year":"2008","unstructured":"Genant HK, Peterfy CG, Westhovens R et al (2008) Abatacept inhibits structural damage progression in rheumatoid arthritis: results from the long-term extension of the AIM trial. Ann Rheum Dis 67:1084\u20131089","journal-title":"Ann Rheum Dis"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-008-0964-3.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,14]],"date-time":"2021-09-14T03:46:59Z","timestamp":1631591219000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10067-008-0964-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,8,1]]},"references-count":39,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2008,11]]}},"alternative-id":["964"],"URL":"https:\/\/doi.org\/10.1007\/s10067-008-0964-3","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,8,1]]}}}